GRF.MC - Grifols, S.A.

MCE - MCE Delayed Price. Currency in EUR
24.52
-0.38 (-1.53%)
As of 3:33PM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close24.90
Open24.75
Bid24.49 x 0
Ask24.51 x 0
Day's Range24.43 - 24.88
52 Week Range21.57 - 27.08
Volume199,987
Avg. Volume748,342
Market Cap14.87B
Beta (3Y Monthly)0.38
PE Ratio (TTM)29.51
EPS (TTM)0.83
Earnings DateMay 2, 2019 - May 9, 2019
Forward Dividend & Yield0.29 (1.17%)
Ex-Dividend Date2019-06-07
1y Target Est25.56
  • PR Newswire7 days ago

    Grifols to launch plasma-protein-based bleeding-control solutions

    BARCELONA, Spain, June 19, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL™ fibrin sealant will be the first product it will introduce with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding. Grifols developed VISTASEAL™, which combines two plasma proteins, fibrinogen and thrombin, and is administered with Ethicon's airless spray device technology.

  • Is Rigel Pharmaceuticals a Buy?
    Motley Fool14 days ago

    Is Rigel Pharmaceuticals a Buy?

    The stock rose after a promising full-year 2018 earnings report and then rapidly began sliding back to multiyear lows. What's going on?

  • Do Institutions Own Grifols, S.A. (BME:GRF) Shares?
    Simply Wall St.20 days ago

    Do Institutions Own Grifols, S.A. (BME:GRF) Shares?

    Every investor in Grifols, S.A. (BME:GRF) should be aware of the most powerful shareholder groups. Insiders often own...

  • Moody'slast month

    Grifols World Wide Operations USA, Inc. -- Moody's announces completion of a periodic review of ratings of Grifols S.A.

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Grifols S.A. Paris, May 16, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Grifols S.A. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Rigel Pharmaceuticals Inc (RIGL) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Rigel Pharmaceuticals Inc (RIGL) Q1 2019 Earnings Call Transcript

    RIGL earnings call for the period ending March 31, 2019.

  • PR Newswire2 months ago

    Grifols Announces PharmacyKeeper Bidirectional Integration with Epic

    BARCELONA, Spain, April 30, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, announced today that its PharmacyKeeper Verification IV Workflow Management system now supports bidirectional integration with Epic.

  • PR Newswire2 months ago

    Grifols Announces the Opening of its new Plasma Donor Center in Hinesville, Georgia

    Investing $1.6 million into local community; set to employ over 40 people from the local area HINESVILLE, Ga. , April 29, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest ...

  • What Does Grifols, S.A.'s (BME:GRF) P/E Ratio Tell You?
    Simply Wall St.2 months ago

    What Does Grifols, S.A.'s (BME:GRF) P/E Ratio Tell You?

    This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). To keep it practical, we'll show how Grifols, S.A.'s (BME:GRF) P/E ratio could help you assess the value on offer...

  • PR Newswire2 months ago

    Grifols US donor centers exceed 250,000 pounds of food collected

    - About 20% of children in the U.S. are frequently hungry while nearly 50 million Americans do not get enough to eat. RALEIGH, N.C., April 18, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its U.S. network of over 220 donor centers collaborated with local food banks and pantries to collect more than 250,000 pounds of groceries to help address food insecurity in local communities. According to Feeding America, a leading national hunger non-profit, the 253,000 pounds of food collected translates into 211,000i meals to help support the over 50,000 familiesii that cannot put sufficient food on the table.

  • Grifols donations of blood clotting factor helping people with hemophilia globally
    PR Newswire2 months ago

    Grifols donations of blood clotting factor helping people with hemophilia globally

    - The company has donated more than 100 million international units (IUs) of blood clotting factor medicines globally during multi-year commitment to the WFH in developing regions. - Grifols creates Grifols Humanitarian Awards in Hemophilia to strengthen the global fight against the disease. BARCELONA, Spain, April 15, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with hemophilia in developing regions has surpassed 100 million international units (IUs) in donated blood clotting factor, a protein in blood that controls bleeding.

  • PR Newswire3 months ago

    Grifols 2018 Annual Report on Form 20-F Filed With the SEC on April 5, 2019

    BARCELONA, Spain , April 5, 2019 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2018 Annual Report on Form 20-F with the United ...

  • Grifols, S.A. (BME:GRF): What We Can Expect From This Growth Stock
    Simply Wall St.3 months ago

    Grifols, S.A. (BME:GRF): What We Can Expect From This Growth Stock

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Looking at Grifols, S.A.'s (BME:GRF) earnings update in December 2018, the cons...

  • PR Newswire3 months ago

    Grifols Announces the Opening of its new Plasma Donor Center in Russellville, AR

    Investing $1.8 million into local community; set to employ over 40 people from the local area RUSSELLVILLE, Ark. , March 23, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest ...

  • Reuters4 months ago

    BRIEF-Shanghai RAAS Blood Products' Trading In Shares To Resume On Mar 8

    March 7 (Reuters) - Shanghai Raas Blood Products Co Ltd : * SAYS TRADING IN SHARES TO RESUME ON MAR 8 AFTER IT FORMED STRATEGIC ALLIANCE WITH SPAIN'S GRIFOLS Source text in Chinese: https://bit.ly/2J0iPCX ...

  • Reuters4 months ago

    Spain's Grifols, China's Shanghai RAAS form strategic alliance

    Spanish blood products company Grifols said on Thursday it has signed a strategic alliance with Shanghai RAAS as it looks to increase its sales of plasma-derived products in China. Under the agreement, the Catalan company will take a 26.2 percent stake in Shanghai RAAS in exchange for a stake of 45 percent (with 40 percent voting rights) in its U.S. division Grifols Diagnostic Solutions (GDS). Grifols said that no external financing was required to fund the transaction which is expected to close in the second half of 2019 pending regulatory approval.

  • Should Grifols Be Disappointed With Their 17% Profit?
    Simply Wall St.4 months ago

    Should Grifols Be Disappointed With Their 17% Profit?

    One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks, you could make more than that. ForRead More...

  • Rigel Pharmaceuticals (RIGL) Q4 2018 Earnings Conference Call Transcript
    Motley Fool4 months ago

    Rigel Pharmaceuticals (RIGL) Q4 2018 Earnings Conference Call Transcript

    RIGL earnings call for the period ending December 31, 2018.

  • Grifols PharmacyKeeper Receives KLAS Category Leader Award for Third Consecutive Year
    PR Newswire4 months ago

    Grifols PharmacyKeeper Receives KLAS Category Leader Award for Third Consecutive Year

    This marks the third consecutive year the PharmacyKeeper Verification software has been recognized as the leader in the IV Workflow Management category by KLAS Research, a healthcare IT data and insight-gathering company that collects and publishes impartial research on the software and services used by healthcare providers and payers worldwide. The PharmacyKeeper suite of software applications was developed by MedKeeper, which was acquired by Grifols in January, 2018.

  • Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System
    PR Newswire5 months ago

    Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System

    BARCELONA, Spain, Feb. 7, 2019 /PRNewswire/ -- Grifols, a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that the U.S. Food and Drug Administration (FDA) approved the Procleix Babesia assay, a qualitative assay for the detection of the ribosomal RNA from 4  Babesia species (B. microti, B. duncani, B. divergens, B. venatorum) in individual samples or up to 16 pooled lysed specimens from human donors, including donors of whole blood and blood components for transfusion.

  • What To Know Before Buying Grifols, S.A. (BME:GRF) For Its Dividend
    Simply Wall St.5 months ago

    What To Know Before Buying Grifols, S.A. (BME:GRF) For Its Dividend

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Dividends play an important role in compounding Read More...

  • Benzinga5 months ago

    Rigel Rises On European Marketing Agreement For Autoimmune Drug

    Small-cap biotech Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL )'s shares were advancing Wednesday after it announced an agreement to commercialize fostamatinib, its autoimmune disorder drug. What Happened ...

  • Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe
    PR Newswire5 months ago

    Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe

    - Grifols gains exclusive rights to fostamatinib in all potential indications in Europe and Turkey - Rigel to receive an upfront payment of $30 million , with the potential for $297.5 million in total ...

  • Grifols receives FDA approval of Erytra Eflexis®, the latest advancement in scalable blood typing solutions
    PR Newswire6 months ago

    Grifols receives FDA approval of Erytra Eflexis®, the latest advancement in scalable blood typing solutions

    - Erytra Eflexis is a fully automated, benchtop analyzer that performs pretransfusion compatibility testing - This system incorporates two laboratory configurations in a single instrument, providing laboratory ...

  • A Note On Grifols, S.A.’s (BME:GRF) ROE and Debt To Equity
    Simply Wall St.6 months ago

    A Note On Grifols, S.A.’s (BME:GRF) ROE and Debt To Equity

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...